Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Olympus Challenges Given Imaging In U.S. Capsule Endoscopy Market

This article was originally published in The Gray Sheet

Executive Summary

Olympus launched its Endo Capsule endoscopy system Sept. 17, making it the second ingestible video camera device for diagnosing small bowel abnormalities to reach the U.S. market

You may also be interested in...

Olympus Builds Minimally Invasive Surgery Line With $1.9 Bil. Gyrus Deal

Olympus will expand its focus on minimally invasive surgical offerings by acquiring electrosurgical instrument maker Gyrus Group under a $1.9 billion deal announced Nov. 19

Second Judge Rejects Constitutional Challenges To Medicare Price Negotiation Program

Delaware district judge rules against AstraZeneca’s claim the IRA violates its due process rights, echoing findings made by Ohio district judge in Chamber of Commerce’s suit. Only other IRA ruling to date dismissed PhRMA’s complaint on procedural grounds without addressing the merits.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts